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SUMMARY: Poliomyelitis associated with live strain vaccine is defined as the paralytic form of the acute anterior poliomyelitis
related to the vaccine strain. Since these strains behave similarly to the wild-type virus, we can differentiate, epidemiologically, two
types of vaccine-associated poliomyelitis: cases in which the patient was vaccinated and cases in which the patient had had contact
with vaccinated individuals. We herein present the case of an unvaccinated child, with a clinical picture of an acute anterior poliomyelitis
associated with the live strain vaccine, whose brother received the Sabin vaccine 20 days before the onset of the symptoms. Vaccine
strain of the type 3 poliovirus was isolated in fecal culture and a  presented mutation in nucleotide 472 (C→U) in the 5’ non-coding
region, which is strongly related to the higher strain virulence.
DESCRIPTORS:  Poliomyelitis.  Vaccine-associated poliomyelitis. Domiciliary transmission.
Live strain vaccine-associated po-
liomyelitis (VAP) is defined as the
paralytic form of the acute anterior po-
liomyelitis related to the vaccine strain
(VS). Since VS acts similarly to the
wild-type virus (WS) with intestinal
replication and fecal elimination, it is
possible to differentiate epidemiologi-
cally two types of VAP:  a) cases where
the patient was vaccinated and  b) cases
where the patient has had contact with
vaccinated individuals. The average in-
terval between vaccination and devel-
opment of symptoms is 31 days and an
accurate diagnosis requires isolation of
VS through culture and identification
by polymerase chain reaction (PCR).
Polioviruses are enteroviruses from
the Picornaviridae family that have an
icosahedral particle formed by 60 cop-
ies of each of the four proteic capsids,
VP1 to VP4, and a RNA genome with
approximately 7 500 nucleotides 1. Ac-
cording to the capsid antigenicity, it is
possible to identify three polioviruses
serotypes designated as: 1, 2, and 3.
The three VS strains (Sabin strains
1, 2, and 3) differ from the WS by mu-
tations in nucleotide 472 in the 5’ non-
coding region and in nucleotide 2034,
which reduce virus replication in the
human intestine and cause changes in
the structural protein amino acids af-
fecting viral replication at high tem-
peratures. VS presents mutation rever-
sion 72 hours after vaccine administra-
tion 2,3,4.  All three VS strains may re-
vert to WS; however, Sabin strain 1 is
very safe and rarely associated with
VAP; VS-2 is safe for vaccinated indi-
viduals, but may be responsible for
some cases of paralysis in contacts, and
VS-3 is the most genetically unstable
and it is accountable for the majority
of  VAP cases.
The estimated VAP frequency in
the United States (US) is 1 case in 2
400 000 doses in vaccinated patients5,
similar to what was estimated in Latin
America during the period 1989-1991
(1 case in 1 500 000 to 2 200 000
doses) 6 . The risk is higher after the
first dose, 1 in 500 000 doses in recipi-
ents, and 1 in 760 000 doses, among
those persons who had had contact
with vaccinees5,7 and declines substan-
tially in the subsequent doses. In Bra-
zil the frequency in this risk has been
estimated as 1 case in 4 400 000 to 6
700 000 doses in all children vacci-
nated and as 1 in 6 700 000–15 500
000 doses in communicants.  In first-
time vaccinees, the risk was 10 to 15
times higher. For immunocompetent
patients who developed VAP, there is
no contraindication for receiving the
subsequent doses. Immunodeficient in-
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dividuals have a higher estimated risk
of developing VAP (3 200–6 800 times
higher) 8; 18% of the  cases were de-
scribed in this group, especially in chil-
dren with hypogammaglobulinemia or
agammaglobulinemia. In the US,
among 125 reported cases, 49 (39%)
occurred in immunocompetent recipi-
ents, 78% of them in the first dose,
93% during the first year of life; and
40 (32%) occurred in immunocompe-
tent contacts and 24% in immunodefi-
cient vaccinees or contacts7. For the lat-
ter groups, it is recommended that im-
munization be done with the inacti-
vated vaccine9, 10.
Healthy unvaccinated adults and
children infected with human immuno-
deficiency virus (HIV) also are groups
with a higher risk for VAP. Two VAP
cases were described in children
HIV+11, 12, but as since benefits of vac-
cination outweigh the risk of infection
by the wild poliomyelitis virus, the
World Health Organization still recom-
mends the use of live strain vaccine for
these patients in developing countries13.
We describe a case of VAP, aiming
to alert pediatricians and neurologists
to the possibility of diagnosing polio-
myelitis associated with the vaccine,
even in infants who have not received
the vaccine but have had contact with
vaccinees, as well as about the neces-
sary procedures for obtaining the de-
finitive diagnosis.
CASE REPORT
A white, 6-month-old male from
Osasco, São Paulo, was admitted with
a prodromic picture of fever and irri-
tability for the previous12 days, fol-
lowed by a generalized weakness. The
patient had an incorrect vaccination
schedule and, due to maternal neglect,
did not receive the Sabin vaccine.
However, he had contact with his 4-
year-old brother who was vaccinated
during a vaccine campaign (lot S.1957-
A1A, Smith Kline) 20 days before the
onset of the clinical picture. No further
cases of adverse events were reported
in other children vaccinated with this
lot, according to the São Paulo State
Immunization Program.
With regard to his personal and
family history, no reference has been
made to recent use of intramuscular-
route medications, repetitive infections,
or immunodeficiency. The patient re-
ceived only BCG and a single dose of
DPT vaccines at 4 months of age.
The first clinical examination
showed a poor appearance, fever, and
tachypnea and the neurological exami-
nation revealed a flaccid and areflexic
tetraplegia without meningeal signs.
The patient developed respiratory fail-
ure associated with autonomic distur-
bances (sweating and arterial hyperten-
sion) 12 hours after hospitalization.
Subsequently, the respiratory pattern
improved and mechanical ventilation
was suspended; nevertheless, the flac-
cid tetraplegia remained and, almost a
month later, the first symptoms of tho-
racic and limb muscular atrophy ap-
peared.
Initial cerebrospinal fluid (CSF)
exam showed cytological protein dis-
sociation; this evolved with a cellular-
ity reduction and a moderate increase
of protein levels (Table 1).
Electroneuromyographic examina-
tion disclosed signs of severe, asym-
metric, and exclusive motor axonal de-
generation affecting all limbs, with no
signs of demyelination, a typical pat-
tern of anterior horn cell disease. The
levels of immunoglobulins (IgG, IgM,
IgA and IgG subclasses) were normal,
and HIV serologic test was negative.
Poliovirus 3 serologic titres indi-
cated a significant increase between the
two samples collected (Table 2). In the
faecal culture in animal and human-
origin cells (Hep-2C and RD) carried
out at the Instituto Adolfo Lutz of São
Paulo, a virus was isolated, and its
serotyping by neutralizing tests with a
specific equine and hyperimmune se-
rum indicated the presence of a polio-
virus 3. The final identification of the
virus was obtained through hybridiza-
tion techniques made with genotypic
catheter and PCR analysis, and re-
vealed mutation in nucleotide 472
(C→U) in the 5’ non-coding region
which defined this as a vaccine strain.
COMMENTS
The oral poliomyelitis virus vac-
cine, which is composed of live attenu-
ated poliovirus (Sabin vaccine), is still
the vaccine chosen in countries like
Brazil due to the advantages of this
vaccine over the injectable one using
inactivated virus (Salk vaccine). Some
of the advantages are: the possibility of
Table 1 – Characteristics of the cerebrospinal fluid.
Days after admission
0 1 5
Days after the onset of symptoms
12 13 18
Data
Erythrocyte/ mm3 04 43 88
Cells/ mm3 66 03 4.6
Lymphocytes 67% – 93%
Reticular monocytes 31% – 03%
Neutrophils 01% – 04%
Protein (mg/dl) 20 50 141
Glucose (mg/dl) 45 76 102
Chlorate (mg/dl) – 725 666
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VS disseminating among the popula-
tion, conferring protection to unvacci-
nated people, easy administration, and
low cost14, 15.
In the US, eight cases of VAP per
year are estimated to occur; 76–88%
occur after the first and second doses
of the vaccine10. In Brazil, the exact
number of confirmed VAP cases is un-
known 6. Immunological disturbances
(mainly, combined immunodeficiency
and hypogammaglobulinemia or agam-
maglobulinemia), first vaccinal dose,
and contact between non-vaccinated
and newly-vaccinated individuals are
considered as conditions of higher risk
for VAP, as was the case herein de-
scribed on which the delay in taking
the first dose means a higher risk for
VAP. After the second month of life,
maternal antibodies are at very low or
absent levels, facilitating an increased
dissemination of the vaccinal virus16.
Similar to poliomyelitis caused by the
wild virus, intramuscular injections
during viral incubation period are also
considered as a risk factor for VAP15.
VAP clinical symptoms are likely
the same as those of the poliomyelitis
caused by VS, including respiratory
failure due to paralysis of the dia-
phragm and intercostal musculature
such as what occurred with the patient
under discussion, who had what is con-
sidered a severe form. Usually sensory
symptoms are absent, but radicular and
meningeal compromising signs may be
disappearing when motor deficit im-
proves and atrophies emerge. The hy-
potonia and the reduction or absence of
reflexes are quite clear. The clinical
picture begins between 4 and 40 days
after the patient is vaccinated, and mo-
tor sequelae compatible with poliomy-
elitis occur 60 days after the onset of
the deficit 17. In cases of contacts, the
flaccid paralysis arises between 4 and
85 days after vaccination, with trans-
mission occurring by direct contact or
oral-fecal route.
This patient’s CSF pointed to the
classic pattern of cito-proteic dissocia-
tion evolving to a moderate protein in-
crease, as has been classically attrib-
uted to acute poliomyelitis;
electroneuromyographic examination
carried out at the sequel phase pointed
to anterior horn cell disease.
Etiological diagnosis of poliomy-
elitis was confirmed based on serologic
study of two samples obtained in the
acute and convalescent phase, respec-
tively, that showed a more than 4-fold
increase in the type 3 titre, indicating
recent infection.
In order to confirm the diagnosis of
VAP, the isolation of vaccinal poliovi-
rus in faeces culture from two samples
collected during the first 14 days after
the establishment of the motor deficit
is essential. As vaccinal enteroviruses
may still be eliminated through the fe-
ces for up to two months after contact,
even in samples collected 15–40 days
after onset of symptoms, CV isolation
confirms diagnosis of VAP. Virus iso-
lation in CSF is an exception18. In VAP
cases, type setting and characterization
(wild or vaccinal) through molecular
hybridization and PCR, as well as
nucleotide sequencing, are important to
clearly define the responsibility of the
attenuated virus in the clinical picture
and to a better understanding of the
poliovirus biology, and to eliminate or
reduce adverse effects associated with
the Sabin vaccine15.
In our country, Friedreich and
colleagues described 8 cases of VAP
with isolation of type 3 VS during
1990-1992; four of these patients were
under 1 year of age, and in 3 of them
the clinical picture developed after the
first dose 2,19.
In 1995, after successful mass im-
munization campaigns with the live
strain vaccine and the important efforts
undertaken by the epidemiological sur-
veillance from 1980 to 1994, the au-
tochthonous transmission of the wild
poliovirus was considered eradicated in
Brazil and in the Americas.
Since then, controversies on even-
tual changes in the vaccination pro-
gram have been the subject of intensive
discussion in countries where the wild
poliomyelitis was brought under con-
trol.  In some European countries and
in the US, it is suggested that the first
doses should be made with the inacti-
vated virus vaccine, followed by a
schedule of vaccines with attenuated
virus. Theoretically, this change in the
immunization calendar would prevent
50 to 70% of VAP cases 7, 14, 20, mainly
in patients who are immunocompetent;
nonetheless, it would not completely
protect immunodeficient patients
against VAP, for whom it is also rec-
ommended that household members
avoid attenuated virus vaccination.
In Brazil, changes in the immuniza-
tion program against poliomyelitis are
not yet discussed due to increase in
costs, low compliance to the intramus-
cular vaccine, precarious sanitary con-
ditions, and the fact that VS persistence
in other regions worldwide would facili-
tate reintroduction and dissemination of
the poliovirus all over the country.
It is important to remember that
young people under 15 years of age
presenting a sudden flaccid motor defi-
cit, regardless of the assumption of a
polio diagnosis, should be reported to
the epidemiological surveillance sys-
tem and investigated through fecal col-
lection to isolate the poliovirus and
verify the diagnosis of poliomyelitis.
Table 2 – Poliovirus serologic study (ELISA) in 2 samples.
  Serologic reaction at admission 21 days after admission
Poliovirus 1 1:32 1:64
Poliovirus 2 <1:8 1:16
Poliovirus 3 1:128 >1:1024
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A poliomielite associada à vacina
oral é definida como a forma paralíti-
ca da poliomielite anterior aguda de-
corrente da cepa vacinal. Uma vez que
o  comportamento da cepa vacinal é
semelhante ao do vírus selvagem,
epidemiologicamente podemos distin-
guir dois tipos de poliomielite associ-
ada à vacina, os casos em que o paci-
ente foi vacinado e os casos em que o
paciente teve contato com pessoas que
receberam a vacina. Apresentamos o
caso de um lactente não vacinado, que
apresentou quadro de poliomielite an-
terior aguda associada à vacina oral,
cujo irmão havia recebido a vacina
Sabin 20 dias antes do início do qua-
dro clínico. Na cultura de fezes do pa-
ciente foi isolado o poliovírus tipo 3,
cepa vacinal, que apresentava mutação
do nucleotídeo 472 (Cfi U) na região
5’ não codificadora, a qual está signi-
ficativamente relacionada com a mai-
or virulência da cepa.
DESCRITORES:  Poliomielite.
Poliomielite pós-vacinal.  Transmis-
são domiciliar.
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